09.02.2017 22:10:00

Nevro to Report Operating Results for the Fourth Quarter and Full Year 2016

REDWOOD CITY, Calif., Feb. 9, 2017 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative evidence-based solutions for the treatment of chronic pain, today announced that it will release financial results for the fourth quarter and full year of 2016 after market close on Thursday, February 23, 2017. Company management will host a conference call beginning at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) on Thursday, February 23, 2017.

Investors interested in listening to the conference call may do so by dialing (877) 201-0168 for U.S. callers, or (647) 788-4901 for international callers (Conference ID: 65198382), or from the webcast on the "Investors" section of the Company's website at www.nevro.com/investors. Following the call, a replay will be available on the Investor Events and Presentations webpage of the Company's website.

About Nevro
Headquartered in Redwood City, California, Nevro is a global medical device company focused on providing innovative products that improve the quality of life of patients suffering from debilitating chronic pain. Nevro has developed and commercialized the Senza spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform for the treatment of chronic pain. The Senza system is the only SCS system that delivers Nevro's proprietary HF10 therapy. Senza, HF10, Nevro and the Nevro logo are trademarks of Nevro.

Investor Relations Contact:
Nevro Investor Relations
Katherine Bock
(650) 433-3247
ir@nevro.com

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/nevro-to-report-operating-results-for-the-fourth-quarter-and-full-year-2016-300405232.html

SOURCE Nevro Corp.

Analysen zu Nevro Corpmehr Analysen

Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!

Aktien in diesem Artikel

Nevro Corp 4,00 0,00% Nevro Corp